Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in relapsed or refractory NK/T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and other non-Hodgkin lymphoma
CTR20222866Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emfizatamab in natural killer/T-cell lymphoma (NKTL), angioimmunoblastic T-cell lymphoma (AITL), non-Hodgkin lymphoma (NHL), sponsored by Biokin Pharmaceutical. Started Mar 2023; status: active.
02
Drugs
emfizatamab
03
Conditions
natural killer/T-cell lymphoma (NKTL)angioimmunoblastic T-cell lymphoma (AITL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20222866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222866.